LifeVest® Wearable Defibrillator Aids Beta-Blocker Optimization in Women
ZOLL announced that insights from the LifeVest® wearable cardioverter defibrillator have assisted physicians in achieving improved heart rate control in female patients. This advancement is associated with more efficient beta-blocker optimization and potentially better survival outcomes. The findings highlight the effectiveness of the wearable defibrillator in enhancing patient care.
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that insights from the LifeVest® wearable cardioverter defibrillator (WCD) helped physicians achieve better heart rate control in female patients – an indicator of more rapid beta-blocker optimization and an outcome associated with improved survival. These findings come from the Optimizing Beta‑Blocker Dosage in Female Patients Using the Wearable Cardiove